A Study to Evaluate the Long-Term Safety of BLI5100 in Patients With Gastroesophageal Reflux Disease

NCT05890001 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

400

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-erosive Reflux Disease
Erosive Esophagitis

Interventions

DRUG: BLI5100

Sponsor

Braintree Laboratories